替米沙坦治疗轻中度原发性高血压疗效和安全性观察

摘要

Objective To observe the efficacy and safety of telmisartan in patients of essential hypertension.Methods This study was a randomized,double-blind and parallel controlled trial.66 eligible mild and moderate hypertension patients were divided randomly into telmisartan group and perindopril group.80mg of telmisartan or 4mg of perindopril was administrated once per day,and the patients were followed up in every two weeks.This trial was continued for 8 weeks.Results After 8 weeks,the effectiveness of telmisartan and perindopril were 72.7% and 68.8%respectively,showing no significant difference between both groups.After 8 weeks,the SBP and DBP of telmisartan group decreased 11.4%and 12.3%.perindopril group decreased 8.9%and 11.1%.Also no significant difference Was observed.The side effect ratio Was significantly lower in telmisartan group(3.2%)than that in perindopril group(15.2%).The most common side effects were COUgh and mild dizziness.Conclusion Telmisartan (80 mg/d)is effective、safe and well tolerated in treatment of mild to moderate essential hypertension.%目的 观察替米沙坦治疗轻中度原发性高血压痛的疗效和安全性.方法 采用随机双盲平行对照试验的方法 将符合条件的轻中度原发性高血压患者66例分为替米沙坦组和培哚普利组各33例,2组分别口服替米沙坦80 mg和培哚普利4 mg,均1次/d,疗程共8周.结果 ①治疗8周后,替米沙坦组降压总有效率72.7%,培哚普利组总有效率68.8%,2组差异无统计学意义(P＜0.05).②治疗前后收缩压、舒张压下降幅度分别为:替米沙坦组11.4%和12.3%,培哚普利组8.9%和11.1%,2组比较无统计学意义(P＞0.05).③不良反应的发生率,替米沙坦组为3.2%,培哚普利组为15.2%,2组差异有统计学意义(P＜0.05).结论 替米沙坦治疗轻中度原发性高血压安全有效,不良反应发生率低于培哚普利.